Vallon Pharmaceuticals stock plunges 70% after ADHD drug candidate misses primary endpoint By: Philadelphia Business Journal via Business Journals March 21, 2022 at 11:02 AM EDT The company suffered a setback with its proprietary abuse-deterrent formulation of dextroamphetamine to treat ADHD. Read More >>
